Cited by 267Dementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative DiseasesAlzheimer's disease research and treatments

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

Open access

Lopez, O L, Becker, J T, Wahed, A S, Saxton, J, Sweet, R A, Wolk, D A, Klunk, W, DeKosky, S T·2009·Journal of Neurology, Neurosurgery & Psychiatry

DOI 10.1136/jnnp.2008.158964PMC PMC2823571

Open this paper in CoChat — free account

Abstract

BACKGROUND: Patients using cholinesterase inhibitors (ChEIs) have a delay in nursing home (NH) admission compared with those who were not using the medication. There are no long-term studies of the effects of memantine in combination with ChEIs use in Alzheimer disease (AD). This study was conducted to examine the effects of ChEIs and memantine on time to death and time to NH admission. METHODS: Time to NH admission and death was examined in 943 probable AD patients who had at least a 1-year follow-up evaluation. Of these patients, 140 (14.9%) used both ChEIs and memantine, 387 (41%) [corrected] used only ChEIs, and 416 (44.1%) [corrected] used neither. The mean (SD) follow-up time was 62.3 (35.8) months. The analysis was conducted with multivariable Cox proportional hazard models controlling for critical covariates (ie, age, education level, gender, severity of the dementia, hypertension, diabetes mellitus, heart disease, psychiatric symptoms and use of psychotropic medications). RESULTS: Compared with those who never used cognitive enhancers, patients who used ChEIs had a significant delay in NH admission (HR: 0.37, 95% CI 0.27 to 0.49); this effect was significantly augmented with the addition of memantine (HR: 0.29, 95% CI 0.11 to 0.72) (memantine+ChEI vs ChEI alone). ChEIs alone, or in combination with memantine had no significant association on time to death. CONCLUSIONS: This observational study revealed that the addition of the NMDA receptor antagonist memantine to the treatment of AD with ChEI significantly altered the treated history of AD by extending time to nursing home admission.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/jnnp.2008.158964

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
A rating scale for depression
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
[Japanese version of the Neuropsychiatric Inventory--a scoring system for neuropsychiatric disturbance in dementia patients].
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Special Care Units and Traditional Care in Dementia: Relationship with Behavior, Cognition, Functional Status and Quality of Life - A Review
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
VALIDITY OF THE TRAIL MAKING TEST AS AN INDICATOR OF ORGANIC BRAIN DAMAGE
Reitan, R. M. (1958) · Perceptual and Motor Skills · doi:10.2466/pms.1958.8.3.271 · Cited by 8,167

Flagged first, then by citations

Show all 56 references

Research works printed but not linked: 1

[32]APA Diagnostic and statistical manual on mental disorders—Revised (DSM-III-R) 1987 3rd edn. Washington, DC American Psychiatric Press

Sorted by citations

Items 101–200 of 267

Association of Antidementia Drugs and Mortality in Community-Dwelling Frail Older Patients With Dementia: The Role of Mortality Risk Assessment
Pilotto, A., Polidori, M. C., Veronese, N., Panza, F., Arboretti, R., Pilotto, A., Daragjati, J., Carrozzo, E., Prete, C., Gallina, P., et al. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.08.017 · Cited by 26
Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer)
Tifratène, K., Duff, F. L., Pradier, C., Quetel, J., Lafay, P., Schück, S., Benzenine, É., Quantin, C., & Robert, P. H. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3303 · Cited by 25
Memantine benefits functional abilities in moderate to severe Alzheimer's disease
Winblad, B. G., Gauthier, S. G., Åström, D. O., & Stender, K. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0122-x · Cited by 24
The South African Society of Psychiatrists (SASOP) Treatment Guidlelines for Psychiatric Disorders
Emsley, R. A., Flisher, A. J., Grobler, G. P., Seedat, S., & Szabo, C. P. (2013) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v19i3.942 · Cited by 25
Economic Evaluation of the Impact of Memantine on Time to Nursing Home Admission in the Treatment of Alzheimer Disease
Lachaîne, J., Beauchemin, C., Legault, M., & Bineau, S. (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105601005 · Cited by 24
Validity, Significance, Strengths, Limitations, and Evidentiary Value of Real-World Clinical Data for Combination Therapy in Alzheimer’s Disease: Comparison of Efficacy and Effectiveness Studies
Atri, A., Rountree, S. D., López, O. L., & Doody, R. S. (2012) · Neurodegenerative Diseases · doi:10.1159/000335156 · Cited by 23
Survival and early recourse to care for dementia: A population based study
Pimouguet, C., Delva, F., Goff, M. L., Stern, Y., Pasquier, F., Berr, C., Tzourio, C., Dartigues, J., & Helmer, C. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.512 · Cited by 23
A Retrospective Study on the Benefits of Combined Citicoline, Memantine, and Acetylcholinesterase Inhibitor Treatments in Older Patients Affected with Alzheimer’s Disease
Castagna, A., Fabbo, A., Manzo, C., Lacava, R., Ruberto, C., & Ruotolo, G. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201211 · Cited by 22
Diverse Molecular Targets for Therapeutic Strategies in Alzheimer's Disease
Han, S.-H., & Mook‐Jung, I. (2014) · Journal of Korean Medical Science · doi:10.3346/jkms.2014.29.7.893 · Cited by 23
Response to Rivastigmine Transdermal Patch or Memantine plus Rivastigmine Patch is affected by Apolipoprotein E Genotype in Alzheimer Patients
Han, H. J., Kim, B. C., Lee, J., Ryu, S., Na, H. R., Yoon, S. J., Park, H. Y., Shin, J. H., Cho, S., Yi, H.-A., et al. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000342927 · Cited by 21
Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use
Wübbeler, M., Wucherer, D., Hertel, J., Michalowsky, B., Heinrich, S., Meyer, S., Schäfer‐Walkmann, S., Hoffmann, W. U., & Thyrian, J. R. (2015) · BMC Health Services Research · doi:10.1186/s12913-015-0855-7 · Cited by 20
Combined Memantine and Donepezil Treatment Improves Behavioral and Psychological Symptoms of Dementia-Like Behaviors in Olfactory Bulbectomized Mice
Yabuki, Y., Matsuo, K., Hirano, K., Shinoda, Y., Moriguchi, S., & Fukunaga, K. (2017) · Pharmacology · doi:10.1159/000452839 · Cited by 20
Combination treatments in Alzheimer’s disease: risks and benefits
Sobów, T. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.43 · Cited by 20
Association of Antidementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer Disease
San-Juan-Rodriguez, A., Zhang, Y., He, M., & Hernandez, I. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.0213 · Cited by 19
Comparison of Adverse Drug Reactions with Donepezil versus Memantine: Analysis of the French Pharmacovigilance Database
Babai, S., Auriche, P., & Le-Louët, H. (2010) · Therapies · doi:10.2515/therapie/2010008 · Cited by 19
Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection
Blasco, H., Patin, F., Andres, C. R., Corcia, P., & Gordon, P. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1202919 · Cited by 19
The Impact of Memantine and Cholinesterase Inhibitor Initiation for Alzheimer Disease on the Use of Antipsychotic Agents: Analysis Using the Régie de l'Assurance Maladie du Québec Database
Lachaîne, J., Beauchemin, C., Crochard, A., & Bineau, S. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/070674371305800404 · Cited by 19
Memantine is Associated with Longer Survival than Donepezil in a Veterans Affairs Prescription Database, 1997 to 2008
Lazzeroni, L. C., Halbauer, J. D., Ashford, J. W., Noda, A. M., Hernandez, B., Azor, V., Hozack, N. E., Hasson, N. K., Henderson, V. W., Yesavage, J. A., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130662 · Cited by 17
Can Persistence With Cholinesterase Inhibitor Treatment Lower Mortality and Health-Care Costs Among Patients With Alzheimer’s Disease? A Population-Based Study in Taiwan
Ku, L. E., Li, C., & Sun, Y. (2017) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317517734639 · Cited by 17
Combination Therapy for the Treatment of Alzheimer’s Disease: Recent Progress and Future Prospects
Shirbhate, E., Patel, V. K., Tiwari, P., Kore, R., Veerasamy, R., Mishra, A., & Rajak, H. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220907114443 · Cited by 18
Health Among the Elderly in Germany. New Evidence on Disease, Disability and Care Need
Doblhammer, G. (2014) · Verlag Barbara Budrich eBooks · doi:10.3224/84740606 · Cited by 16
Efficacy and Tolerability of a Combination Treatment of Memantine and Donepezil for Alzheimer's Disease: A Literature Review Evidence.
Riverol, M., Slachevsky, A., & López, O. L. (2011) · PubMed · Cited by 16
The Therapeutic Potential of Epigenetic Modifications in Alzheimer’s Disease
Bufill, E., Nogué, R. R., & Blesa, R. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch9 · Cited by 15
Cryptotanshinone Attenuates Amyloid-β42-induced Tau Phosphorylation by Regulating PI3K/Akt/GSK3β Pathway in HT22 Cells
Lyu, D., & Jia, J. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02850-2 · Cited by 16
Cholinesterase inhibitors and memantine are associated with a reduced mortality in nursing home residents with dementia: a longitudinal observational study
Havreng‐Théry, C., Oquendo, B., Zolnowski‐Kolp, V., Krolak‐Salmon, P., Bertin‐Hugault, F., Lafuente‐Lafuente, C., & Belmin, J. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01481-0 · Cited by 16
Alzheimer’s dementia: budget impact and cost-utility analysis of a combination treatment with a cholinesterase inhibitor and memantine in Switzerland
Pfeil, A. M., Kressig, R. W., & Szucs, T. D. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13676 · Cited by 15
Institutionalization of Older People: Prediction and Prevention
Brown, S. H. M., & Abdelhafiz, A. H. (2011) · Aging Health · doi:10.2217/ahe.10.88 · Cited by 15
A pharmacoeconomic evaluation of cholinesterase inhibitors and memantine for the treatment of Alzheimer’s disease
Ebrahem, A. S., & Oremus, M. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1499727 · Cited by 15
Outpatient management of patients with dyscirculatory encephalopathy
Parfenov, V. A., & Неверовский, Д. В. (2015) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2015-1-37-42 · Cited by 16
Survival in a Large Elderly Population of Patients with Dementia and Other Forms of Psychogeriatric Diseases
Nilsson, K., Gustafson, L., & Hultberg, B. L. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000335728 · Cited by 14
Extract of Caragana sinica as a potential therapeutic option for increasing alpha-secretase gene expression
Schuck, F., Schmitt, U., Reinhardt, S., Freese, C., Lee, I., Thines, E., Efferth, T., & Endres, K. (2015) · Phytomedicine · doi:10.1016/j.phymed.2015.08.001 · Cited by 14
Therapeutic Targets in Innate Immunity to Tackle Alzheimer’s Disease
Serradas, M. L., Ding, Y., Martorell, P., Kulińska, I., & Castro‐Gomez, S. (2024) · Cells · doi:10.3390/cells13171426 · Cited by 16
Beneficial Effects of an Integrated Psychostimulation Program in Patients with Alzheimer’s Disease
Ibarria, M., Alegret, M., Valero, S., Morera, A., Guitart, M., Cañabate, P., Moreno, M., Lara, S., Diego, S., Hernández, J., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150455 · Cited by 15
Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine
Jiang, X., Liu, C., Zou, M., Xie, H., Lin, T., Lyu, W., Xu, J., Li, Y., Feng, F., Sun, H., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113663 · Cited by 13
Diagnosis and management of early‐onset dementia
Davies, R., Doran, M., & Larner, A. J. (2011) · Progress in Neurology and Psychiatry · doi:10.1002/pnp.205 · Cited by 13
Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease
Hu, Z., Wang, L., Ma, S., Kirisci, L., Feng, Z., Xue, Y., Klunk, W. E., Kamboh, M. I., Sweet, R. A., Becker, J. T., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.09.001 · Cited by 13
COGNOS
Mets, T. F., Deyn, P. P. D., Pals, P., Lepeleire, J. D., Vandewoude, M. F. J., Ventura, M., Ivanoiu, A., Albert, A., & Seghers, A.-K. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318256d1d0 · Cited by 12
Pharmacological treatment for Alzheimer's disease: current approaches and future strategies.
Fan, L., & Chiu, M. (2010) · PubMed · Cited by 11
Memantine in moderate to severe Alzheimer’s disease: an observational post-marketing study
Rainer, M. K., Wuschitz, A., Jagsch, C., Erb, C., Chirikdjian, J.-J., & Mucke, H. A. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0623-8 · Cited by 12
Memantine in Alzheimer’s disease: experience in an Alzheimer’s disease assessment unit
Sinforiani, E., Pasotti, C., Chiapella, L., Malinverni, P., & Zucchella, C. (2012) · Aging Clinical and Experimental Research · doi:10.1007/bf03325164 · Cited by 13
POST HOC EVIDENCE FOR AN ADDITIVE EFFECT OF MEMANTINE AND DONEPEZIL: CONSISTENT FINDINGS FROM DOMINO-AD STUDY AND MEMANTINE CLINICAL TRIAL PROGRAM
Hendrix, S. B., Ellison, N., Stanworth, S., Otcheretko, V., & Tariot, P. N. (2015) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2015.66 · Cited by 11
Past and Future of Drug Treatments for Alzheimer's Disease
Kim, S. Y. (2018) · 신경정신의학 · doi:10.4306/jknpa.2018.57.1.30 · Cited by 11
Cognitive Enhancers in Moderate to Severe Alzheimer's Disease
Hardeland, R. (2011) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s6344 · Cited by 9
Could cholinesterase inhibitors be harmful over the long term?
Schneider, L. S. (2011) · International Psychogeriatrics · doi:10.1017/s1041610211002389 · Cited by 10
Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region
Sabbagh, M. N., Han, S., Kim, S., Na, H. R., Lee, J., Kandiah, N., Phanthumchinda, K., Suthisisang, C. C., Senanarong, V., Pai, M., et al. (2016) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000448214 · Cited by 10
Use of anti-dementia drugs and delayed care home placement: an observational study
Salib, E., & Thompson, J. (2011) · The Psychiatrist · doi:10.1192/pb.bp.110.033431 · Cited by 10
Persistence and adherence to rivastigmine in patients with dementia: Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan
Chang, C., Chou, T., Chang, C., Chen, T., Hu, C., Fuh, J., Wang, W., Chen, C., Hsu, W., & Huang, C. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.013 · Cited by 10
Recent Advances in the Treatment and Management of Alzheimer’s Disease: A Precision Medicine Perspective
Shukla, D., Suryavanshi, A., Bharti, S. K., Asati, V., & Mahapatra, D. K. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266299847240328045737 · Cited by 10
Pyridoindole antioxidant-induced preservation of rat hippocampal pyramidal cell number linked with reduction of oxidative stress yet without influence on cognitive deterioration in Alzheimer-like neurodegeneration.
Gáspárová, Z., Stara, V., Janega, P., Navarová, J., Sedláčková, N., Mach, M., & Ujházy, E. (2014) · PubMed · Cited by 9
Alzheimer’s Treatment: Real-World Physician Behavior Across Countries
Podhorná, J., Winter, N., Zoebelein, H., & Perkins, T. (2020) · Advances in Therapy · doi:10.1007/s12325-019-01213-z · Cited by 9
Optimizing Diagnosis and Management in mild-to-moderate Alzheimer’s Disease
Galvin, J. E. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.21 · Cited by 9
Early Start of Anti-Dementia Medication Delays Transition to 24-Hour Care in Alzheimer’s Disease Patients: A Finnish Nationwide Cohort Study
Halminen, O., Vesikansa, A., Mehtälä, J., Hörhammer, I., Mikkola, T. M., Virta, L. J., Ylisaukko‐oja, T., & Linna, M. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201502 · Cited by 9
Combination Drug Therapy for the Treatment of Alzheimer’s Disease
Alvarez, X. A., Linares, C., & Masliah, E. (2012) · European Neurological Review · doi:10.17925/enr.2012.07.02.92 · Cited by 9
Medikamentöse Therapie demenzieller Erkrankungen
Kraft, J. W. (2017) · Der Internist · doi:10.1007/s00108-016-0180-1 · Cited by 6
Tratamiento farmacológico de la demencia: cuándo, cómo y hasta cuándo. Recomendaciones del Grupo de Trabajo de Demencias de la Sociedad Catalana de Geriatría y Gerontología
Rodríguez, D., Formiga, F., Fort, I., Robles, M. J., Barranco, E., & Cubí, D. (2012) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2012.02.008 · Cited by 8
P3‐362: DEMENTIA AND LONG‐TERM CARE: AN ANALYSIS BASED ON GERMAN HEALTH INSURANCE DATA
Fink, A., & Doblhammer, G. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.05.1456 · Cited by 7
Pharmacological Treatment of Alzheimer’s Disease
Schneider, L. S. (2012) · Advances in biological psychiatry · doi:10.1159/000335407 · Cited by 7
Can small molecules provide truly effective enhancement of cognition? Current achievements and future directions
Plath, N., Lerdrup, L., Larsen, P. H., & Redrobe, J. P. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.574612 · Cited by 7
Can Acupuncture Treat Alzheimer’s Disease and Other Neurodegenerative Disorders?
Asakawa, T., & Xia, Y. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3357-6_8 · Cited by 7
Risk of Long-Term Care Dependence for Dementia Patients is Associated with Type of Physician: An Analysis of German Health Claims Data for the Years 2006 to 2010
Fink, A., & Doblhammer, G. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142082 · Cited by 7
Lecanemab for Alzheimer Disease
Nelson, S. E., & López, O. L. (2024) · Neurology · doi:10.1212/wnl.0000000000209265 · Cited by 7
Use of Anti-Dementia Drugs in Relation to Change in Cognition, Behavior, and Functioning in Alzheimer’s Disease over a Three-Year Period: Kuopio ALSOVA Study
Törmälehto, S., Martikainen, J. A., Väätäinen, S. T., Hallikainen, I. T., Hallikainen, M., Bell, J. S., Koivisto, A. M., & and on the behalf of the ALSOVA study group (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150092 · Cited by 6
Evolución del consumo de fármacos específicos para la demencia en la comunidad autónoma de Madrid durante el periodo 2002-2012
de Hoyos-Alonso, M. C., Tapias-Merino, E., Barros, C. M. M., Sánchez-Martínez, M., & Otero, Á. (2014) · Neurología · doi:10.1016/j.nrl.2014.02.007 · Cited by 6
Memantin als Add-on-Medikation zur Acetylcholinesteraseinhibitor-Therapie bei Alzheimer-Demenz
Haußmann, R., & Donix, M. (2016) · Der Nervenarzt · doi:10.1007/s00115-016-0237-3 · Cited by 6
Depression, family and immunity: influence of humoral immunity on family relationships and on the severity of depression.
Tomasović, S., Sremec, J., Košćak, J., Klepac, N., Draganić, P., & Bielen, I. (2016) · PubMed · Cited by 6
Pharmacological treatment for Alzheimer’s disease
Kulkantrakorn, K. (2014) · Asian Medical Journal and Alternative Medicine · doi:10.70933/2773-9465.1545 · Cited by 6
Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias
Perez, Y. P., & Hughes, D. A. (2024) · PharmacoEconomics · doi:10.1007/s40273-024-01418-3 · Cited by 5
Demenz vom Alzheimer-Typ: Nicht-medikamentöse und medikamentöse Therapie
Kressig, R. W. (2015) · Therapeutische Umschau · doi:10.1024/0040-5930/a000670 · Cited by 6
Traitement symptomatique de la maladie d’Alzheimer et perspectives thérapeutiques
Forette, F., & Hauw, J. (2010) · Therapies · doi:10.2515/therapie/2010055 · Cited by 7
Benefits and Risks of Add-On Therapies for Alzheimer’s Disease
Magierski, R., & Sobów, T. (2015) · Neurodegenerative Disease Management · doi:10.2217/nmt.15.39 · Cited by 6
Treatment for Alzheimer's diseases
Tyuvina, N. A., & Владимировна, Б. В. (2015) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2015-3-80-85 · Cited by 5
Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer's disease
Kano, O., Urita, Y., Ito, Takazawa, Kawase, Y., Murata, Hirayama, Miura, M., Ishikawa, F., Kiyozuka, et al. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s50135 · Cited by 5
Persistence with Cholinesterase Inhibitor Treatment in Alzheimer's Disease
Massoud, F. (2013) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100014815 · Cited by 5
Atypical Alzheimer's disease
Sha, S. J., & Rabinovici, G. D. (2016) · Wiley eBooks · doi:10.1002/9781118797662.ch3 · Cited by 5
Mortality and institutionalization of patients with dementia treated in primary care: influence of neuropsychiatric symptoms (NeDEM project)
García-Martín, V., de Hoyos-Alonso, M., Martín‐Fernández, J., & del Cura-González, I. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06339-0 · Cited by 4
Memantine: A Treatment for Alzheimer’s Disease with a New Formulation
Makino, K. M., & Porsteinsson, A. P. (2011) · Aging Health · doi:10.2217/ahe.11.31 · Cited by 4
Long-term use of pharmacological treatment in Alzheimer’s disease: a retrospective cohort study in real-world clinical practice
Lombardi, G., Lombardi, N., Bettiol, A., Crescioli, G., Ferrari, C., Lucidi, G., Polito, C., Berti, V., Bessi, V., Bagnoli, S., et al. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03325-y · Cited by 4
Changes in Antidementia Medications upon Admission to the Nursing Home: Who Decides and Why? Results From a National Survey of Nursing Home Administrators
Lapane, K. L., Ott, B. R., Hargraves, J. L., Cosenza, C. A., Liang, S., & Alcusky, M. J. (2023) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2023.09.022 · Cited by 4
Pharmaceutical Use and Spending Trend in Medicare Beneficiaries With Dementia, From 2006 to 2012
Hernandez, I., & Zhang, Y. (2017) · Gerontology and Geriatric Medicine · doi:10.1177/2333721417704946 · Cited by 4
Pharmacological Therapies in Alzheimer's Disease
Steinberg, M., & Lyketsos, C. G. (2010) · doi:10.1002/9780470669600.ch52 · Cited by 4
Natural Plant‐Derived Acetylcholinesterase Inhibitors: Relevance for Alzheimer's Disease
Braidy, N., Poljak, A., Jayasena, T., & Sachdev, P. S. (2017) · Wiley eBooks · doi:10.1002/9783527805921.ch12 · Cited by 5
Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024
Saleh, A. Y., Saputra, D. A. Y., Valentina, R., & Susanto, T. D. (2025) · F1000Research · doi:10.12688/f1000research.160416.3 · Cited by 1
FACEmemory®, an Innovative Online Platform for Episodic Memory Pre-Screening: Findings from the First 3,000 Participants
Alegret, M., García‐Gutiérrez, F., Muñoz, N., Espinosa, A., Ortega, G., Lleonart, N., Rodríguez, I., Rosende‐Roca, M., Pytel, V., Cantero‐Fortiz, Y., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230983 · Cited by 3
Drug Treatments for Alzheimer’s Disease: Hopes and Challenges
Braidy, N., Poljak, A., Jayasena, T., & Sachdev, P. S. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_141 · Cited by 2
In-silico Studies and Biological Activity of Potential BACE-1 Inhibitors
Arya, R., Paliwal, S., Gupta, S. P., Sharma, S. K., Madan, K., Mishra, A., Verma, K., & Chauhan, N. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323999200918151331 · Cited by 3
16-Year Survival of the Canadian Collaborative Cohort of Related Dementias
Lichtenstein, M. L., Fallah, N., Mudge, B., Hsiung, G. R., Foti, D. J., Beattie, B. L., & Feldman, H. (2018) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2018.6 · Cited by 3
Therapeutics of Alzheimer’s Disease
Herrera-Rivero, M., & Emiliano, G. (2011) · InTech eBooks · doi:10.5772/27990 · Cited by 3
Pharmacoeconomics of Alzheimer’s disease (AD) treatment with cholinesterase inhibitors
Versijpt, J. J. (2012) · Acta Neurologica Belgica · doi:10.1007/s13760-012-0062-9 · Cited by 3
Implications of the impact survey for payors across Europe
Forette, F., Padovani, A., Berthet, K., & Knox, S. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0267-7 · Cited by 3
Consumption trends for specific drugs used to treat dementia in the region of Madrid (Spain) from 2002 to 2012
de Hoyos-Alonso, M. C., Tapias-Merino, E., Barros, C. M. M., Sánchez-Martínez, M., & Otero, Á. (2015) · Neurología (English Edition) · doi:10.1016/j.nrleng.2014.02.005 · Cited by 3
Two Drugs Are Not Better Than One for Treating Moderate to Severe Alzheimer Disease, British Investigators Report
Shaw, G. (2012) · Neurology Today · doi:10.1097/01.nt.0000414612.08062.70 · Cited by 3
Neurocognitive Disorders in Old Age: Alzheimer’s Disease, Frontotemporal Dementia, Dementia with Lewy Bodies, and Prion and Infectious Diseases
von Gunten, A., Nogueira, E. L., Parmentier, H., & Gomes, I. (2019) · Springer eBooks · doi:10.1007/978-3-030-10814-4_21 · Cited by 3
Comparative analysis of the effectiveness of donepezil monotherapy and combination therapy with donepezil and akatinol memantine in patients with Alzheimer's disease at the stage of mild dementia
Ткачева, О. Н., Рунихина, Н. К., Mkhitaryan, E. A., Koberskaya, N. N., & Маневич, Т. М. (2020) · Russian neurological Journal · doi:10.30629/2658-7947-2019-24-5-54-60 · Cited by 3
Agitation in Patients with Dementia - Challenges in Diagnosis and Treatment
Sommer, O. H. (2010) · NORA - Norwegian Open Research Archives · Cited by 3
Immunotherapies: A Treasure Trove of Alzheimer's Disease
Kolay, A., Neelam, N., Gupta, P., Shaikh, A. M., Goel, R., Nagpal, D., & Chitme, H. R. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010308600240709052539 · Cited by 2
The Value of Positron Emission Tomography for Confirmation of Alzheimer’s Disease in the Era of Amyloid-Targeting Therapies
Veljanoska, E., Gomes, S., Szende, Á., Cabra, A., Munter-Young, R., & Gordois, A. (2025) · Value in Health · doi:10.1016/j.jval.2025.02.011 · Cited by 2
Antidementia drugs and nursing home placement: a systematic review and meta-analysis
Rattanatanyapat, P., Suan-ek, P., Saokaew, S., Phisalprapa, P., & Mongkhon, P. (2026) · European Geriatric Medicine · doi:10.1007/s41999-025-01398-3 · Cited by 3
Cholinesterase inhibitors in dementias
Mecocci, P., Paolacci, L., & Boccardi, V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815854-8.00029-x
Spezielle Aspekte bezogen auf Organsysteme nach geriatrisch-klinischer Bedeutung
Wehling, M., Burkhardt, H., Schwarz, S. T., Frölich, L., & Wedding, U. (2016) · Springer eBooks · doi:10.1007/978-3-662-48126-4_2 · Cited by 2
Pharmaceutical Care in Outpatients with Dementia at Nakhon Ratchasima Rajanagarinda Psychiatric Hospital
Rungruang, K. (2011) · Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci) · doi:10.14456/ijps.2011.7 · Cited by 2

Authors: Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T.
Affiliations: University of Pittsburgh (US)
ORCID: Becker, J T
Wahed, A S
Sweet, R A
Wolk, D A
Klunk, W
DeKosky, S T
Venue: Journal of Neurology, Neurosurgery & Psychiatry
Publisher: BMJ
Published: 2009-02-09
Volume: 80
Issue: 6
Pages: 600-607
ISSN: 0022-3050 (ISSN-L)
DOI: 10.1136/jnnp.2008.158964
PMC: PMC2823571
OpenAlex: W2171545307
Cited by: 266
References: 56
Citations by year: 2026: 6 · 2025: 7 · 2024: 10 · 2023: 5 · 2022: 9 · 2021: 5 · 2020: 11 · 2019: 7 · 2018: 14 · 2017: 14 · 2016: 18 · 2015: 26 · 2014: 18 · 2013: 25 · 2012: 30
FWCI: 18.51
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
HighWire Press Open Archive (submittedVersion)
Funders: National Institutes of Health (5p01ag003705-04)
National Institute on Aging (AG 05-133, AG 20098, AG027224, P50AG005133, U01AG016976, AG 03705, R01AG020098, AG-16976, R56AG020098, R01AG027224)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: Alzheimer's disease, memantine, cholinesterase inhibitors, combination therapy, nursing home admission, time to death, NMDA receptor antagonists, long-term effects
MeSH terms: Aged, Aged, 80 and over, Alzheimer Disease, Cholinesterase Inhibitors, Drug Therapy, Combination, Female, Follow-Up Studies, Homes for the Aged, Humans, Male, Memantine, Mental Status Schedule, Neuropsychological Tests, Nursing Homes, Patient Admission, Survival Analysis, Excitatory Amino Acid Antagonists, Nootropic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks